ArticleAdvanced healthcare materials2026
Tailoring NIR-II Fluorescence and Photothermal Properties via Side-Chain Engineering for Vascular Imaging and Image-Guided Tumor Therapy.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Second near-infrared (NIR-II, 1000-1700 nm) fluorescence imaging (FLI)-guided photothermal therapy is a promising non-invasive strategy for tumor theranostics. However, existing photothermal agents struggle to balance high photothermal conversion efficiency (PCE) with strong fluorescence quantum yield (QY). Herein, an alkoxyl side chain engineering strategy was proposed to construct a series of donor-π bridge-acceptor-π bridge-donor (D-π-A-π-D) structured organic photothermal agents (TTQ1-TTQ6) enabling simultaneous NIR-II FLI-guided photothermal therapy. By introducing different alkoxyl side chains on triphenylamine donor or thiophene π-bridge, the photophysical properties including aggregation-induced emission (AIE) property, QY and PCE were regulated. TTQ2 NPs and TTQ6 NPs featured superior resolution and low background in in vivo NIR-II fluorescence imaging of the mouse blood vessels with high signal-to-noise ratio. Four alkoxyl chains attached to the donor moiety enhanced the intramolecular donor-acceptor interaction and effectively suppressed aggregation-caused quenching (ACQ), enabling TTQ6 NPs to exhibit desirable NIR-II fluorescence and a high PCE of 46.5%. Encouragingly, TTQ6 NPs could effectively ablate both subcutaneous and orthotopic breast tumors and stimulate adaptive immune responses, which collectively reduced the risk of tumor recurrence. This study illustrates the potential of alkoxyl side chain engineering strategy in developing advanced photothermal agents for NIR-II FLI-guided theranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.